Skip to content

On this page

Lytenava

bevacizumab-vikg

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Lytenava

Proper name

bevacizumab-vikg

Licence type

351(a)

BLA number

761320

Applicant

Outlook Therapeutics, Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
1.25MG (0.05ML of 25MG/ML)	Injection	Intravitreal	Single-Dose Vial	Rx	July 24, 2026

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity